Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -3.77%33 10-Year Share Buyback Ratio is -27.20 as of Jun. 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 448 Medical Devices & Instruments companies, Standard BioTools ranks worse than 89.06% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Standard BioTools's current 10-Year Share Buyback Ratio was -27.20%.
LAB's 10-Year Share Buyback Ratio is ranked worse than 89.06% of 448
companies
in the Medical Devices & Instruments industry
Industry Median: -3.3
vs LAB: -27.20
Standard BioTools (NAS:LAB) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Standard BioTools 10-Year Share Buyback Ratio Related Terms
LAB vs CV, ELMD, CATX: 10-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Standard BioTools's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools 10-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Standard BioTools's 10-Year Share Buyback Ratio falls into.
Standard BioTools 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -27.20 mean?
Standard BioTools (LAB) has a 10-Year Share Buyback Ratio of -27.20 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #399 out of 448 companies in the Medical Devices & Instruments industry, placing it in the top 89.1%.
Is Standard BioTools' 10-Year Share Buyback Ratio too high?
Standard BioTools' current 10-Year Share Buyback Ratio is -27.20. Based on the distribution chart, Standard BioTools ranks #399 out of 448 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' 10-Year Share Buyback Ratio compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #399 out of 448 companies for 10-Year Share Buyback Ratio. This places Standard BioTools in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 10-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Standard BioTools and its competitors. Standard BioTools's current 10-Year Share Buyback Ratio is -27.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 9% below its estimated fair value. The current 10-Year Share Buyback Ratio is -27.20. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Standard BioTools (LAB), the current 10-Year Share Buyback Ratio is -27.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 9% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Modestly Undervalued.
Key valuation signals for LAB:
10-Year Share Buyback Ratio: -27.20
GF Value™: $0.71 vs. price of $0.65 (9% below fair value)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
